JPMorgan Chase & Co. Has $84,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE)

JPMorgan Chase & Co. increased its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE) by 106.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 11,997 shares of the company’s stock after acquiring an additional 6,181 shares during the period. JPMorgan Chase & Co.’s holdings in NeuroPace were worth $84,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Financial Advocates Investment Management lifted its position in shares of NeuroPace by 20.0% during the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after buying an additional 3,000 shares during the period. Barclays PLC increased its position in NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after buying an additional 16,007 shares during the last quarter. State Street Corp grew its position in shares of NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Geode Capital Management LLC grew its position in NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after buying an additional 25,330 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Buying and Selling

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of NeuroPace stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the sale, the insider now owns 87,062 shares of the company’s stock, valued at approximately $1,306,800.62. The trade was a 3.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.20% of the stock is owned by company insiders.

NeuroPace Stock Down 1.1 %

Shares of NASDAQ:NPCE opened at $13.61 on Tuesday. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The stock has a market capitalization of $406.26 million, a P/E ratio of -13.61 and a beta of 2.05. NeuroPace, Inc. has a 12-month low of $5.45 and a 12-month high of $18.15. The stock’s 50-day moving average price is $11.89 and its 200-day moving average price is $8.92.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The business had revenue of $21.06 million for the quarter, compared to analysts’ expectations of $19.33 million. During the same period in the previous year, the firm posted ($0.28) EPS. On average, equities analysts anticipate that NeuroPace, Inc. will post -1 earnings per share for the current year.

Analyst Ratings Changes

NPCE has been the subject of a number of research reports. UBS Group started coverage on NeuroPace in a research note on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price target for the company. JPMorgan Chase & Co. upped their target price on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company increased their target price on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.80.

NeuroPace Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.